GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaLundensis AB (XSAT:PHAL) » Definitions » Shiller PE Ratio

PharmaLundensis AB (XSAT:PHAL) Shiller PE Ratio : (As of Jun. 10, 2024)


View and export this data going back to 2010. Start your Free Trial

What is PharmaLundensis AB Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


PharmaLundensis AB Shiller PE Ratio Historical Data

The historical data trend for PharmaLundensis AB's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaLundensis AB Shiller PE Ratio Chart

PharmaLundensis AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PharmaLundensis AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PharmaLundensis AB's Shiller PE Ratio

For the Biotechnology subindustry, PharmaLundensis AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaLundensis AB's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaLundensis AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where PharmaLundensis AB's Shiller PE Ratio falls into.



PharmaLundensis AB Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

PharmaLundensis AB's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, PharmaLundensis AB's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.03/132.2054*132.2054
=-0.030

Current CPI (Mar. 2024) = 132.2054.

PharmaLundensis AB Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.095 100.432 -0.125
201409 -0.069 100.161 -0.091
201412 -0.058 100.225 -0.077
201503 -0.034 99.950 -0.045
201506 -0.043 99.995 -0.057
201509 -0.060 100.228 -0.079
201512 -0.052 100.276 -0.069
201603 -0.026 100.751 -0.034
201606 -0.069 101.019 -0.090
201609 -0.052 101.138 -0.068
201612 -0.043 102.022 -0.056
201703 -0.052 102.022 -0.067
201706 -0.069 102.752 -0.089
201709 -0.060 103.279 -0.077
201712 -0.314 103.793 -0.400
201803 -0.052 103.962 -0.066
201806 -0.079 104.875 -0.100
201809 -0.044 105.679 -0.055
201812 -0.052 105.912 -0.065
201903 -0.044 105.886 -0.055
201906 -0.070 106.742 -0.087
201909 -0.044 107.214 -0.054
201912 -0.055 107.766 -0.067
202003 -0.026 106.563 -0.032
202006 -0.035 107.498 -0.043
202009 -0.088 107.635 -0.108
202012 -0.097 108.296 -0.118
202103 -0.018 108.360 -0.022
202106 -0.026 108.928 -0.032
202109 -0.018 110.338 -0.022
202112 -0.018 112.486 -0.021
202203 -0.044 114.825 -0.051
202206 -0.018 118.384 -0.020
202209 -0.018 122.296 -0.019
202212 -0.030 126.365 -0.031
202303 -0.020 127.042 -0.021
202306 -0.027 129.407 -0.028
202309 -0.027 130.224 -0.027
202312 -0.036 131.912 -0.036
202403 -0.030 132.205 -0.030

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


PharmaLundensis AB  (XSAT:PHAL) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


PharmaLundensis AB Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of PharmaLundensis AB's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaLundensis AB (XSAT:PHAL) Business Description

Traded in Other Exchanges
N/A
Address
Medicon Village, Scheelevagen 2, Lund, SWE, 22381
PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.

PharmaLundensis AB (XSAT:PHAL) Headlines

No Headlines